The primary objective of this study is to assess progression free survival (PFS) with proposed therapy for patients with locally advanced or metastatic gallbladder and biliary cancers. every 9 weeks [clinicaltrials_resource:607d9951e09d20ace436f146b9c882ed]
Estimate the toxicity of the regimen, and estimate the quality of life (QOL).
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
The primary objective of this study is to assess progression free survival (PFS) with proposed therapy for patients with locally advanced or metastatic gallbladder and biliary cancers. every 9 weeks [clinicaltrials_resource:607d9951e09d20ace436f146b9c882ed]
Estimate the toxicity of the regimen, and estimate the quality of life (QOL).
Bio2RDF identifier
607d9951e09d20ace436f146b9c882ed
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:607d9951e09d20ace436f146b9c882ed
measure [clinicaltrials_vocabulary:measure]
The primary objective of this ...... llbladder and biliary cancers.
time frame [clinicaltrials_vocabulary:time-frame]
every 9 weeks
description
Estimate the toxicity of the regimen, and estimate the quality of life (QOL).
identifier
clinicaltrials_resource:607d9951e09d20ace436f146b9c882ed
title
The primary objective of this ...... biliary cancers. every 9 weeks
@en
type
label
The primary objective of this ...... d9951e09d20ace436f146b9c882ed]
@en